Drug Database
RE

recombinant human insulin (insulin, HEC Pharm)

✓ Approved

HEC Pharm · INSR · 重组蛋白

什么是 recombinant human insulin?

recombinant human insulin 是一种重组蛋白,由HEC Pharm研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名insulin, HEC Pharm
公司HEC Pharm
药物类别重组蛋白
分子靶点INSR
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

recombinant human insulin 作用于 1 个分子靶点:

INSRinsulin receptor (CD220, HHF5)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

recombinant human insulin 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersType 1 diabetes mellitus✓ Approved
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

相关研究文献

PubMedDrugs2026-11-17

Insulin Efsitora Alfa: First Approval.

Blair Hannah A HA

Insulin efsitora alfa (Onswik™) is a once-weekly ultra-long-acting recombinant basal insulin being developed by Eli Lilly and Company for the treatment of diabetes mellitus. Administered once weekly as a subcutaneous injection, insulin efsitora alfa is designed to provide a simplified treatment regimen relative to standard daily basal insulins. On 20 August 2026, insulin efsitora alfa received its first approval in the EU for the treatment of type 2 diabetes mellitus (T2DM) in adults. On 24 September 2026, insulin efsitora alfa was approved in the USA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Insulin efsitora alfa is approved in the EU, Iceland, Norway, Liechtenstein and the USA and is under regulatory review in the UK and Japan for T2DM. This article summarizes the milestones in the development of insulin efsitora alfa leading to this first approval for T2DM.

PMID 43040187
阅读全文 →
PubMedThe Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association2026-11-17

Safety of Recombinant Human Bone Morphogenetic Protein-2 Versus Iliac Crest Bone Graft in Alveolar Cleft Repair: Systematic Review and Meta-Analysis.

Alhamdan Abdulla A, Demetriou Efthimios E, Almeer Mohammad M, Demosthenous Christoforos C et al.

ObjectiveTo compare the safety and complication profiles of recombinant human bone morphogenetic protein (rhBMP-2) and iliac crest bone graft (ICBG) in alveolar cleft repair.DesignA systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and prospectively registered with PROSPERO (CRD420261340773).SettingPublished comparative studies identified through a comprehensive search of PubMed/MEDLINE, Embase and CENTRAL up to September 2026.Patients, Participants808 patients undergoing alveolar cleft repair, 395 with ICBG, 413 with rhBMP-2; across 7 studies (2 RCTs, 5 observational studies).InterventionsRhBMP-2 versus ICBG.Main Outcome MeasuresPrimary outcomes are graft failure, infection, oronasal fistula formation, postoperative swelling and wound dehiscence; secondary outcomes were operative time, length of stay and cost.ResultsSeven studies were included in the analysis. There were no statistically significant differences observed in graft failure (odds ratio [OR] = 0.86, 95% confidence interval [CI] 0.43-1.71, P = 0.67), wound dehiscence (OR = 1.33; 0.57-3.14) and fistula formation (OR = 0.46; 0.04-5.05). RhBMP-2 was associated with lower postoperative infection rates (OR = 0.20; 0.05-0.72; P = 0.01), although it was also associated with higher postoperative swelling (OR = 9.74, 95% CI 3.91-24.27, P < 0.00001). However, certainty of the evidence remained low.ConclusionsAlthough rhBMP-2 may be associated with lower infection rates, the increased postoperative swelling risk remains a concern. The limited number of studies, predominantly observational evidence, imprecision and heterogeneity limit the interpretation of these findings. Adequately powered RCTs are needed to establish the safety of rhBMP-2 relative to ICBG.

PMID 43042568
阅读全文 →
PubMedArchives of physiology and biochemistry2026-11-17

Netrin-3 attenuates metabolic dysfunction-associated fatty liver disease by activating the AMPK-PPARα axis.

Hong Zhenfei Z, Dong Feng F

Metabolic dysfunction-associated fatty liver disease (MAFLD) is characterized by hepatic steatosis and can progress to steatohepatitis. Netrin-3, an axon guidance protein linked to metabolic homeostasis, has not been characterized in MAFLD. MAFLD was induced in mice by high-fat diet. Netrin-3 and UNC5A expression was measured in serum and liver. Recombinant Netrin-3 was administered with or without Compound C. Hepatic AMPK/ACC phosphorylation, PPARα and target genes, lipid and glucose profiles, insulin, and liver injury were assessed. AML12 hepatocytes with fatty acid overload were treated with Netrin-3, Compound C, or AMPKα siRNA. Netrin-3 and UNC5A were downregulated in MAFLD mice. Netrin-3 treatment reduced body weight, adiposity, dyslipidemia, hyperglycemia, hyperinsulinemia, ALT/AST levels, and hepatic steatosis. It increased AMPK and ACC phosphorylation and restored PPARα, Fabp1, and CPT1α expression. Compound C reversed these protective effects in vivo. In AML12 cells, Netrin-3 activated AMPK/ACC signaling, and this effect was abolished by Compound C and AMPKα siRNA. Netrin-3 attenuates MAFLD progression by activating the hepatic AMPK-PPARα axis and promoting fatty acid oxidation, identifying Netrin-3 as a candidate therapeutic molecule for fatty liver disease.

PMID 43043069
阅读全文 →
PubMedNature metabolism2026-11-17

Plasma proteomics identifies insulin resistance signatures predictive of cardiometabolic disease risk.

Kjærgaard Jeppe J, Kurgan Nigel N, Gräf Justus F JF, Zhang Naixin N et al.

Insulin resistance drives cardiometabolic disease, yet its molecular signatures and tissue origins remain incompletely characterized. Here we define a circulating protein signature that enables scalable assessment of insulin sensitivity. We applied multiworkflow proteomics to plasma from 161 individuals spanning the insulin sensitivity spectrum defined by the hyperinsulinaemic-euglycaemic clamp and identified 488 proteins associated with insulin sensitivity, capturing contributions from liver, adipose tissue and immune cells. A subset of these proteins shifted towards a more insulin-sensitive profile following an exercise intervention in men. We further developed a model combining 13 proteins, including IGFBP1, LEP, GDF15, PON3 and LDLR, with clinical variables (sex, HbA1c and the triglyceride-to-high-density lipoprotein cholesterol ratio) to predict insulin sensitivity (R2 = 0.67). In ~20,000 UK Biobank participants, the model outperformed the triglyceride-to-high-density lipoprotein cholesterol ratio in predicting type 2 diabetes (concordance index, 0.86 versus 0.74) and, unlike HbA1c, predicted hepatic, renal, cardiovascular and respiratory disease. In an independent cohort of 1,700 individuals, the model also showed greater predictive utility than fasting insulin resistance indices, including the homeostatic model assessment of insulin resistance. Together, these findings establish a tissue-resolved plasma proteomic framework for characterizing insulin resistance and provide a scalable approach to precision cardiometabolic risk stratification.

PMID 43040099
阅读全文 →
PubMedMicrobial cell factories2026-11-17

Construction and immunogenicity evaluation of recombinant Bacillus subtilis expressing VP8 protein of porcine rotavirus.

Wang Zhikui Z, Yan Xinping X, Wang Xu X, Yue Xiaoxue X et al.

Porcine rotavirus (PoRV), an enteric infectious virus, is a major cause of neonatal diarrhea in piglets, resulting in significant economic losses to the global swine industry. In this study, the cholera toxin B subunit (CTB) was utilized as a molecular adjuvant to construct recombinant Bacillus subtilis (B. subtilis) strains expressing VP8 proteins and CTB-VP8 fusion proteins derived from the PoRV genotypes P[7], P[13], and P[23]. The recombinant strains expressing PoRV proteins from different genotypes were combined and orally administered to mice, and their immunogenicity and probiotic functions were evaluated. The results demonstrated that the recombinant B. subtilis significantly increased serum-specific IgG and fecal-specific sIgA antibodies levels (P < 0.001), indicating that the recombinant strains induced both humoral and mucosal antibody responses in mice. Notably, the CTB-fused strains elicited higher titers of IgG and sIgA. Furthermore, the recombinant strains significantly elevated the expression levels of cytokines, including IFN-γ, IL-2, and IL-4, in both serum and intestinal mucosa (P < 0.01), suggesting a Th1/Th2-biased immune response at the cytokine level. In addition, administration of recombinant B. subtilis increased villus height and the villus height-to-crypt depth ratio while reducing crypt depth, showing a tendency to improve intestinal morphology. This study addresses the limitations associated with insufficient mucosal immune activation by conventional injectable approaches and the absence of cross-protection among different genotypes of PoRV, thereby providing a theoretical foundation for the development of an oral trivalent live-vector vaccine.

PMID 43040377
阅读全文 →
PubMedBMC biology2026-11-17

Drosophila CerS homeodomain sites differentially alter insulin resistance.

Vera-Granda Christian C, Sociale Mariangela M, Beckschäfer Konstantin K, Kanevskij Ilja I et al.

Ceramides are central sphingolipid intermediates whose abundance and molecular composition are closely linked to insulin resistance. Ceramide synthases (CerSs) generate ceramides and, in several family members, also contain a conserved homeodomain with poorly understood metabolic functions. Drosophila has a single CerS, Schlank, which contains a catalytic Lag1p motif and two predicted nuclear localization sequences, NLS1 and NLS2. We investigated how distinct Schlank homeodomain mutations affect high-sugar diet (HSD)-induced insulin resistance. Endogenous KINLS1 and KIE118A knock-in alleles retained DNA binding and transcriptional repression under basal conditions but increased susceptibility to HSD-induced metabolic dysfunction. Both mutants developed enhanced hyperglycemia and impaired insulin-responsive tGPH recruitment, while KIE118A additionally showed increased FoxO nuclear localization and DILP2 retention in insulin-producing cells. By contrast, fat-body-specific switching to the DNA-binding-deficient NLS2 variant or the catalytically inactive H215D variant attenuated selected HSD-induced phenotypes, including FoxO nuclear accumulation and DILP2 retention, without fully correcting hyperglycemia or reduced body weight. Lipidomic analysis revealed extensive diet-dependent sphingolipid remodeling. In particular, NLS2 and H215D markedly reduced the fat-body ceramide pool, including abundant d14:1/20:0- and d14:1/22:0-containing Cer, CerPE, and HexCer species. The Schlank homeodomain regulates insulin homeostasis in a site- and tissue-dependent manner. Distinct homeodomain mutations can either increase susceptibility to or partially attenuate HSD-induced insulin resistance, potentially involving insulin signaling, inter-organ communication, and sphingolipid composition.

PMID 43040328
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多recombinant human insulin